Claims for Patent: 8,241,849

Summary for Patent: 8,241,849

Title:	Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
Abstract:	The invention is directed to isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human lipoprotein-associated phospholipase A2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s):	Ryan; James W (Augusta, GA)
Assignee:	Ryogen LLC (Suffern, NY)
Application Number:	12/323,364
Patent Claims:	1. A method of detecting the presence or absence of a polynucleotide in a sample, said polynucleotide selected from the group consisting of: (i) a polynucleotide which is at least 99% identical to the polynucleotide of SEQ ID NO:2, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has human lipoprotein-associated phospholipase A2 activity; (ii) a fragment of (i) comprising at least nucleotides 11967-30301, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has lipoprotein-associated phospholipase A2 activity; and (c) the full complement of (i) or (ii), said method comprising (a) contacting the sample with an isolated polynucleotide probe or primer, wherein said probe or primer is a fragment of a polynucleotide which is at least 99% identical to SEQ ID NO:2 and wherein said polynucleotide probe or primer comprises at least 20 contiguous nucleotides of SEQ ID NO:2 or its full complement which contains a transcription factor binding site at an NFAT_Q6 site at nucleotides 11523-11541, and (b) determining whether the polynucleotide probe or primer binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to said probe or primer in step (a) detects the presence of a polynucleotide comprising SEQ ID NO:2. 2. The method according to claim 1, wherein said sample is contacted with a probe between 50-2000 contiguous nucleotides in length. 3. A method for detecting the presence of a polynucleotide in a sample, said polynucleotide selected from the group consisting of: (i) a polynucleotide which is at least 99% identical to the polynucleotide of SEQ ID NO:2; (ii) a fragment of (i) comprising at least nucleotides 11967-30301 of SEQ ID NO:2, and (iii) the full complement of (i) or (ii) in a sample, comprising (a) contacting the sample with a polynucleotide probe or primer comprising the 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO:2 or its complementary sequence and (b) determining whether the polynucleotide probe or primer binds to said nucleic acid molecule in the sample. 4. The method according to claim 3, wherein the polynucleotide or probe comprises the intron region of SEQ ID NO:2 or its complementary sequence. 5. The method according to claim 1, wherein the polynucleotide or probe is a DNA or RNA sequence. 6. The method according to claim 3, wherein the polynucleotide or probe is a DNA or RNA sequence.

Details for Patent 8,241,849

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-05-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-05-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-05-30